FREEHOLD

Avalon GloboCare Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference

Retrieved on: 
Monday, April 22, 2024
Hack, FDA, Google Play, AI, Health, Diabetes, Conference, Obesity, Exercise, Diet, App Store (iOS/iPadOS), Self-management, Algorithm, Medical device

KetoAir™ is a cutting-edge breathalyzer featuring Hot App shareable technology with AI-enabled software, specifically engineered for ketogenic health management (United States FDA registration number: 3026284320).

Key Points: 
  • KetoAir™ is a cutting-edge breathalyzer featuring Hot App shareable technology with AI-enabled software, specifically engineered for ketogenic health management (United States FDA registration number: 3026284320).
  • Following its launch, consumers will be able to buy the KetoAir™ breathalyzer exclusively at the newly designed website KetoAir.com .
  • “We're excited to announce the official launch of KetoAir™ breathalyzer sales in the U.S. at the Hack Your Health conference,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare.
  • We can't wait to introduce the KetoAir™ to individuals keen on elevating their health and wellness journey.”

Chromocell Issues Letter to Stockholders from Chief Executive Officer

Retrieved on: 
Tuesday, April 9, 2024
Erythromelalgia, Consultant, Toxicity, ChromeOS, Abrasion (medical), Letter, Uveitis, Growth, Opioid, Neuropathic pain, Incidence, Physiology, Patient, NAV, Mortality, IPO, Human, Rash, Outline, Lawyer, Annual report, CHRO, PRK, Pain, Glaucoma, NSAID, Therapy, Family, Photorefractive keratectomy, FDA, Liver, Food, Pharmaceutical industry

We transferred $2.2 million in liabilities to Chromocell Corporation in exchange for 2,600 shares of Series C Convertible Redeemable Preferred Stock (“Series C Preferred Stock”).

Key Points: 
  • We transferred $2.2 million in liabilities to Chromocell Corporation in exchange for 2,600 shares of Series C Convertible Redeemable Preferred Stock (“Series C Preferred Stock”).
  • Our CEO has agreed to further defer a considerable portion of his accrued compensation, affirming the belief in Chromocell’s mission.
  • We truly feel that our IPO and recent therapeutic development activities have positioned Chromocell for long term growth and success.
  • I wish to thank you for your support and remain a resource to each of you as we move forward.

Avalon GloboCare Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, United Kingdom and European Union

Retrieved on: 
Thursday, March 28, 2024
Health, Obesity, Algorithm, Apple, Exercise, Qi, Diabetes, AI, Google Play, European, FDA, Medical device

KetoAir™ is a pioneering breathalyzer device equipped with AI-enabled software, designed for ketogenic health management (United States FDA registration number: 3026284320).

Key Points: 
  • KetoAir™ is a pioneering breathalyzer device equipped with AI-enabled software, designed for ketogenic health management (United States FDA registration number: 3026284320).
  • Moreover, the AI nutritionist within the app offers personalized nutritional and exercise recommendations tailored to each user's health goals.
  • “We are excited to extend our exclusive distribution agreement for KetoAir™ with Qi Diagnostics,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare.
  • “KetoAir™ is the first breathalyzer on the market that uses an AI nutritionist bundled with a nanosensor-based breathalyzer for ketogenic health management.

Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler

Retrieved on: 
Thursday, March 21, 2024
Glaucoma, B&L, Inflammation, Common, Telecanthus, NIH, CHRO, ISTA, Allergan, Pain, Therapy, Poultry farming

FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler.

Key Points: 
  • FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler.
  • The Company believes its sodium channel, NaV1.7 program will be suitable for an array of eye pain indications.
  • Common acute eye pain indications include corneal foreign body damage or abrasion, acute angle closure glaucoma and post-surgical sequelae.
  • “The launch of our eye pain treatment program represents a significant milestone for the Company.

Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023

Retrieved on: 
Monday, March 18, 2024
Knowledge, CHRO, Interim, Therapy

FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its interim CEO Frank Knuettel, has been appointed as the Company’s permanent CEO.

Key Points: 
  • FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its interim CEO Frank Knuettel, has been appointed as the Company’s permanent CEO.
  • “I’m grateful to our board of directors and Chromocell’s investors for their support over the past seven months and for the confidence they have shown in my ability to lead the Company,” said Frank Knuettel, CEO of Chromocell.
  • “I look forward to continuing to work with them and leading the effort to push forward our announced clinical and pre-clinical programs and developing additional programs based on our proprietary non-opioid pain therapy compound.”
    ”Since being appointed Interim CEO, Frank has established himself as a goal-oriented and pragmatic leader,” added Todd Davis, Chairman of the Board of Directors for the Company.
  • “The Board is pleased to remove the “interim” title and believes Frank has the experience, knowledge, and strategic perspective to build our current programs, expand our portfolio of non-opioid pain treatment therapies, and seek suitable monetization of certain programs at the appropriate times.”
    Mr. Knuettel was previously appointed Interim CEO in July 2023, while currently serving as the Company’s CFO, a role he will continue to fill for the near future.

Chromocell to Present at Sidoti Virtual Investor Conference March 13-14

Retrieved on: 
Monday, March 11, 2024
Therapy, CHRO, Conference, Cryptocurrency

AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced Frank Knuettel, CEO, will present and host one-on-one meetings with investors at the Sidoti March Virtual Investor Conference, taking place on March 13-14, 2024.

Key Points: 
  • AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced Frank Knuettel, CEO, will present and host one-on-one meetings with investors at the Sidoti March Virtual Investor Conference, taking place on March 13-14, 2024.
  • Chromocell’s presentation will begin March 13 at 2:30-3:00 PM in Track 3 and can be accessed live here: https://sidoti.zoom.us/webinar/register/WN_D2qavsKxRjOQeRlFjjLw7A .
  • The Company will also host virtual one-on-ones with investors on Wednesday and Thursday, March 13-14, 2024.
  • Registration is free and you don't need to be a Sidoti client.

Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions

Retrieved on: 
Tuesday, February 27, 2024
Therapy, CHRO, FDA, Quality of life, Pain, Organization, Health, Patient, Agreement, Partnership, Pharmaceutical industry

Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Benuvia Operations, LLC (“Benuvia”), a leader in pharmaceutical innovation, and Chromocell Therapeutics Corp. (“Chromocell”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, are pleased to announce Chromocell’s first Development and License Agreement (“Agreement”).

Key Points: 
  • Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Benuvia Operations, LLC (“Benuvia”), a leader in pharmaceutical innovation, and Chromocell Therapeutics Corp. (“Chromocell”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, are pleased to announce Chromocell’s first Development and License Agreement (“Agreement”).
  • This strategic alliance underscores both Benuvia and Chromocell’s commitment to advancing healthcare through innovative research, development, and commercialization efforts.
  • "We are excited to partner with Chromocell, a company that shares our passion for innovation and our commitment to improving patient outcomes," said Darwin Richardson, CEO of Benuvia Operations LLC.
  • "This partnership will leverage our combined expertise to accelerate the development of potentially groundbreaking therapies, aimed at marking a new era in healthcare solutions."

Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million

Retrieved on: 
Wednesday, February 21, 2024
Therapy, Prospectus, CHRO, Manatt, Phelps & Phillips, Sale, Telephone, Madison Avenue, LLP, Security (finance)

FREEHOLD, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell”, “our”, “us” or the “Company”), a clinical-stage biotech company focused on developing and commercializing new, non-opioid therapeutics to alleviate pain, today announced the closing of its initial public offering of 1,100,000 shares of its common stock at a public offering price of $6.00 per share.

Key Points: 
  • FREEHOLD, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell”, “our”, “us” or the “Company”), a clinical-stage biotech company focused on developing and commercializing new, non-opioid therapeutics to alleviate pain, today announced the closing of its initial public offering of 1,100,000 shares of its common stock at a public offering price of $6.00 per share.
  • The gross proceeds from the offering to Chromocell, before deducting the underwriting discounts and estimated offering expenses, were approximately $6.6 million.
  • A.G.P./Alliance Global Partners acted as the sole book-running manager for the public offering.
  • The securities described above were offered by Chromocell pursuant to a registration statement on S-1, as amended (File No.

Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering

Retrieved on: 
Friday, February 16, 2024
Therapy, Prospectus, Neuropathic pain, CHRO, Sale, Form, Telephone, Madison Avenue, Security (finance)

FREEHOLD, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell” or the “Company”), a clinical-stage biotech company focused on developing and commercializing new, non-opioid therapeutics to alleviate pain, today announced the pricing of its initial public offering of 1,100,000 shares of common stock at a public offering price of $6.00 per share.

Key Points: 
  • FREEHOLD, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell” or the “Company”), a clinical-stage biotech company focused on developing and commercializing new, non-opioid therapeutics to alleviate pain, today announced the pricing of its initial public offering of 1,100,000 shares of common stock at a public offering price of $6.00 per share.
  • The offering raised aggregate gross proceeds of approximately $6.6 million, prior to deducting underwriting discounts and other offering expenses.
  • In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 15% of shares of common stock at the initial public offering price, less underwriting discounts, and commissions to cover over-allotments, if any.
  • The offering is expected to close on February 21, 2024, subject to customary closing conditions.

Avalon GloboCare Engages ChtrBx, a Marketing and Branding Company, to Launch KetoAir in the US

Retrieved on: 
Monday, December 18, 2023
Marketing, PR, FDA, Best Buy, European, Health, Kodak, Artificial intelligence, Levi Strauss & Co., Advertising, Qi

In April 2023, Avalon announced that it has partnered with Qi Diagnostics to exclusively distribute the KetoAir™ in North America, South America, the UK and the EU.

Key Points: 
  • In April 2023, Avalon announced that it has partnered with Qi Diagnostics to exclusively distribute the KetoAir™ in North America, South America, the UK and the EU.
  • KetoAir™ functions as a companion diagnostic and monitoring device, combined with an artificial intelligence (AI) nutritionist consultation for ketogenic dietary management (United States FDA registration number: 3026284320).
  • “We are excited to partner with ChtrBx to create a successful marketing plan to launch KetoAir™ in the U.S. and abroad,” commented David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon.
  • We plan to soft launch KetoAir™ in 2024 followed by a hard launch in 2025.”